阿卡波糖（拜唐苹）在中国临床应用经验回顾及展望

Retrospective of Acarbose （ Glucobay ） administration experience in China and its prospectives

作为第一个主要针对餐后血糖控制的降糖药，阿卡波糖（拜唐苹）在中国上市十几年来，得到医生和患者普遍认可，并且已经逐渐成为临床应用最广泛的口服降糖药之一。这与西方国家情况似有不同，是偶然因素还是另有原因？

As the first oral anti-diabetic drug special for post-prandial blood glucose, Acarbose （Giucobay） is well accepted by the Chinese doctors and patients in the past decade, and has become a kind of widelY-used oral antidiabetic drugs, which seems to be different with the western countries. Was it occasional？ Or did it have some unknown reasons？